News

Calixa Therapeutics, a biopharmaceutical company, has reported positive results from a Phase I trial of intravenous CXA-101, a novel cephalosporin antibiotic with excellent in vitro anti-pseudomonal activity. According

The approval was based on results of two randomized, double-blind, active-controlled, multinational studies (studies 308 and 313) that evaluated Tygacil for the treatment of community-acquired bacterial pneumonia (CABP)

ThermoDox is currently being evaluated under a special protocol assessment with the FDA in a 600 patient, global Phase III trial in patients with non-resectable primary liver cancer.

B Braun’s distribution territory will be world-wide, excluding the US, Canada, Mexico, Japan, the Middle East, Australia, New Zealand, Greece, South Africa and China. The definitive agreement is

The main products in Stallergenes’s injectable and sublingual ranges will soon be the subject of registration applications. This partnership reportedly enables Stallergenes to meet more than 80% of

Under the terms of the agreement, the kits will be sold under both companies’ names. Kits will be shipped directly from Stemgent, and representatives from both Stemgent and

According to Quick-Med, the Nimbus is a next-generation wound care technology that is non-toxic, long-lasting and not blocked by organics such as blood, urine and perspiration. Ladd Greeno,

Through the collaboration Biovitrum gains access to the proprietary technology platforms of Affibody molecules, as well as the unique albumin-binding technology for pharmaceuticals development. The agreement consists of

According to Gore, the Excluder AAA endoprosthesis device is an endovascular graft and stent combination that seals off the aneurysm and creates a new path for blood flow.